Pain management and safe prescribing

Education

Physicians Insurance/Experix online continuing medical education on pain management
These activities has been approved for AMA PRA Category 1 Credit™.

A Leader’s Guide
A Leader’s Guide is a shared effort delivered by ControlRx on behalf of Experix, a wholly owned subsidiary of Physicians Insurance A Mutual Company. Your course director is Michael Schiesser MD, an internist and addiction medicine specialist practicing in the state of Washington.

MQAC’s 2012 pain management rules and 2015 AMDG Interagency Guideline CME package
MQAC offers an educational program on the 2012 pain rules, which includes a video the commission has produced which can be part of a free four CME offering available through L&I. This activity has been approved for AMA PRA Category 1 Credit™.

UW TelePain Sessions
The University of Washington Division of Pain Medicine offers weekly UW TelePain sessions, audio and video-based conferences to assist community providers (both primary and specialty) in the management of complex and challenging chronic pain problems. The sessions include:

  • Didactic presentations from the UW Pain Medicine curriculum for primary care providers
  • Case presentations from community clinicians
  • Interactive consultations for providers with an interprofessional panel of specialists
  • The use of measurement-based clinical instruments to assess treatment effectiveness and outcomes for individuals and larger populations

UW TelePain Sessions take place each Wednesday from noon–1:30 p.m. for community health care providers.

Military and VA providers are encouraged to join a special session of UW TelePain focused on military and veterans’ health care on Thursdays from noon–1:30 p.m.

Weekly didactic presentations for primary care providers occur between noon–12:30 p.m. during each broadcast followed by a brief question and answer period. Slides, articles, and references from these presentations are made available to participants.

This activity has been approved for AMA PRA Category 1 Credit™.

ROAM and ECHO: Defeating Opiate Addiction in Rural Washington
Two initiatives to help providers grapple with the disparate problems of addiction and pain management. ROAM (the Rural Opiate Addiction Management) Collaborative, launched by UW Medicine and Washington State University, seeks to help manage the widespread issue of opiate addiction in rural Washington. COPE (Collaborative Opioid Prescribing Education), launched by UW Medicine is an online educational tool that helps providers communicate to patients about how best to manage treatment of chronic, non-cancer-related pain.

ER/LA Opioids: Achieving Safe Use while Improving Patient Care
Developed by the Collaborative for REMS Education (CO*RE) for physicians or physician assistants who prescribe extended-release and long-acting opioid analgesics, this free course offers best-practice strategies and skills to improve therapy adherence and reduce harm. CO*RE—a collaboration between 13 health care professional organizations—was founded in 2010, prior to the release of the Food and Drug Administration’s ER/LA Opioid REMS Blueprint. Visit the CO*RE website to access the course online or search for upcoming in-person events. This activity has been approved for AMA PRA Category 1 Credit™.

Resources

UW Pain Medicine Provider Toolkit
The University of Washington has developed a provider toolkit, which brings together a number of useful, informative, and important resources regarding the treatment of chronic pain and MQAC’s 2012 pain rules.

Pain Medication Safety Guidelines in the Emergency Department
This patient resource for emergency departments was created to help reduce the recent rise in abuse, addiction, overdose, and death from prescription pain medication

Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids
On July 9, 2012, FDA approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications.

ER/LA opioids are highly potent drugs that are approved to treat moderate to severe persistent pain for serious and chronic conditions. The misuse and abuse of these drugs have resulted in a serious public health crisis of addiction, overdose and death.

The REMS is part of a multi-agency federal effort to address the growing problem of prescription drug abuse and misuse. The REMS introduces new safety measures to reduce risks and improve safe use of ER/LA opioids while continuing to provide access to these medications for patients in pain.